RxDoctor Payments Data

Leslie Dally, DO

Addiction Medicine · Bowling Green, KYNPI 1306093877

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.2% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Indivior Inc. at 39.6% of the total. 2025 is the largest year on record at $387, 4.9 times the $79 reported in 2019. That places this record below the midpoint for addiction medicine clinicians in KY, where the typical reported total is $695.

$864in general payments, 2019–2025

Across 43 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$342
  • Braeburn Inc.$172
  • Alkermes, Inc.$119
  • AbbVie$101
  • Gilead$59
  • AstraZeneca$29
  • plus $41 from 3 others

What the payments were for

  • Food & beverage$81494%
  • Education$506%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$864 in reported general payments places this provider in the 50th percentile of 40 addiction medicine providers in Kentucky.

See all addiction medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$14,983
Medicare patients
19
Services billed
140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl318$31,564
ZubsolvBuprenorphine Hcl/Naloxone Hcl13$4,592
SuboxoneBuprenorphine Hcl/Naloxone Hcl12$3,425
Gabapentin50$428
Bupropion XlBupropion Hcl13$116
Trazodone Hcl12$16
Diazepam22$14

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine-Naloxone$14$31,564318 claims
Indivior Inc.Suboxone$342$3,42512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 40 addiction medicine providers in Kentucky.

Other addiction medicine in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →